UNT Health Science Center logo

Posted: October 15, 2001

UNT HEALTH SCIENCE CENTER SEEKS WOMEN WHO SUFFER FROM MENSTRUALLY-ASSOCIATED MIGRAINES FOR DRUG STUDY


FORT WORTH, Texas— Researchers at the University of North Texas Health Science Center are evaluating a new drug that may provide relief from menstrually associated migraines.

The health science center is seeking women who have at least 12-month documented history of experiencing menstrually associated migraine (MAM) headaches. These are migraine headaches that are linked with the time of a woman’s menstrual period. Volunteers must be over the age of 18 and otherwise healthy to participate in the clinical trial.

The purpose of the study is to assess the effectiveness of frovatriptan in preventing MAM headaches. Frovatriptan is a new drug not yet approved for general use by the U.S. Food and Drug Administration.

“Fluctuating hormones often trigger severe headaches for many women, and this clinical trial may identify a new treatment for this debilitating, recurring health issue,” said William McIntosh, DO, chief of neurology at the UNT Health Science Center and the primary investigator in the study.

The health science center is one of 35 sites in the United States seeking a total of 650 patients to enroll in the study.

All study-related medication, tests and procedures will be provided free of charge. Each volunteer will receive $25 per completed study visit for their time and travel expenses. Those interested should call Deborah Griffin, clinical research coordinator, at (817) 735-5127.

If you are with the media and need additional information or would like to arrange an interview,
please contact Jeff Carlton, Director of Media Relations, at 817-735-7630.

 

bottom frame